[{"from": "human", "value": "Describe this molecule. [C][C@@H1][C][C@@H1][Branch2][=Branch1][Ring1][C][N][Branch1][Ring2][C][Ring1][=Branch1][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch2][Ring2][Branch1][=C][C][=C][C][=Branch1][#Branch2][=C][C][Ring1][=Branch1][=C][Ring1][N][N][=O][S][=Branch1][C][=O][=Branch1][C][=O][N][C][C@@H1][Branch1][=Branch2][C][C@@H1][Branch1][Ring2][C][Ring1][=Branch1][C][C][N][O][C]"}, {"from": "gpt", "value": "The molecule is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors."}]